Is Vascular Endothelial Growth Factor (VEGF) Available as a Topical Treatment, or Is It Only Stimulated Indirectly?

Vascular Endothelial Growth Factor, commonly known as VEGF, is a naturally occurring protein in the human body that plays a central role in angiogenesis, which is the formation of new blood vessels. Blood vessels deliver oxygen and nutrients to tissues. Hair follicles, which are the small organs in the skin responsible for producing hair, are highly dependent on an adequate blood supply. In mice, more blood vessels around follicles went with faster regrowth and larger follicles (Yano et al., 2001); whether better blood flow prolongs the growth (anagen) phase in the human scalp has not been shown.

The importance of VEGF in hair biology was clearly demonstrated in 2001 in a transgenic mouse study conducted by Yano et al. Researchers genetically engineered mice to overexpress VEGF in their skin. The study showed increased perifollicular vascularization, meaning more blood vessels formed around hair follicles. These mice developed larger hair follicles and thicker hair shafts. The evaluation method included histological examination of skin samples under microscopy and measurement of hair follicle size. The study was conducted on animals, not humans, and its duration followed the natural hair cycle of mice, which is significantly shorter than that of humans. While the findings support VEGF's role in mouse hair growth, the main criticism is that mouse models do not always translate directly to human physiology.

This foundational evidence established VEGF as a key signaling molecule in hair follicle biology. However, whether VEGF itself can be applied directly as a topical treatment remains a different question.

Is Topical VEGF Available as a Treatment?

At present, VEGF is not approved by the U.S. Food and Drug Administration (FDA) as a topical treatment for hair loss. A review of FDA-approved drugs for androgenetic alopecia, commonly known as male or female pattern hair loss, confirms that only minoxidil (topical) and finasteride (oral, for men) have received approval. No recombinant VEGF-based topical medication is listed in FDA databases for hair restoration.

Recombinant VEGF, which refers to laboratory-produced VEGF protein, has been studied in experimental settings, particularly in wound healing and cardiovascular research. However, VEGF is a large protein molecule. Proteins of this size have difficulty penetrating the outermost layer of human skin, known as the stratum corneum. The stratum corneum acts as a barrier that prevents large molecules from entering the bloodstream or deeper tissues. Without advanced drug delivery systems, VEGF cannot effectively pass through intact human skin.

In addition to penetration challenges, there are safety concerns. VEGF promotes blood vessel formation. While this is beneficial in controlled settings, uncontrolled angiogenesis may theoretically increase the risk of tumor growth, as tumors also rely on blood vessel formation. Reviews of VEGF biology describe its role in tumour blood-vessel growth, and several cancer and eye medicines work by blocking it (Ferrara, 2004). For this reason, systemic manipulation of VEGF must be approached cautiously. This safety profile makes widespread cosmetic use of topical VEGF unlikely without rigorous long-term trials.

Currently, no large-scale, peer-reviewed human clinical trials have demonstrated that topical VEGF alone is safe and effective for treating androgenetic alopecia.

If VEGF Is Not Applied Directly, How Is It Stimulated?

Although direct topical VEGF is not available, minoxidil (an approved drug) and two procedures still under study, microneedling and PRP, are thought to increase VEGF expression indirectly. Microneedling and PRP are not approved hair-loss treatments. This means they stimulate the body’s own production of VEGF within the scalp.

**One of the most well-studied examples is minoxidil. A 1998 study by Lachgar et al. investigated minoxidil’s effects on cultured human dermal papilla cells, which are specialized cells at the base of **hair follicles that regulate hair growth. The study used in vitro cell cultures and measured VEGF levels using molecular assays. The researchers found that minoxidil increased VEGF expression in these cells. The limitation of this study is that it was performed on isolated cells in laboratory conditions rather than on living human subjects. It suggests one possible mechanism for part of minoxidil’s effect.

Microneedling, a procedure still under study, is thought to raise growth factors such as VEGF. A 2013 randomized controlled trial by Dhurat et al. compared microneedling combined with minoxidil versus minoxidil alone in men with androgenetic alopecia. The study included 100 male participants over 12 weeks. Hair count was assessed using standardized photography and dermoscopy. The microneedling group showed significantly greater improvement. The study did not measure VEGF in participants; the idea that microneedling works through growth factors released during wound healing is a hypothesis. The criticism of this study includes its relatively short duration and limited long-term follow-up.

Platelet-rich plasma (PRP) is another example. PRP involves concentrating a patient’s own platelets and injecting them into the scalp. Platelets release growth factors, including VEGF. A 2015 randomized, placebo-controlled half-head trial by Gentile et al. analysed 20 people with pattern hair loss who had three PRP sessions a month apart. The authors reported higher hair counts and density after treatment compared with the patients' own baseline, and a slight increase in small blood vessels around follicles in biopsies compared with baseline; 3 of the 23 people enrolled were excluded. The trial was small, PRP protocols vary widely, and PRP is not an approved hair-loss treatment.

In all these cases, VEGF is stimulated indirectly as part of a broader biological cascade rather than delivered directly as a standalone topical drug.

What Does the Scientific Community Conclude?

**Published research suggests that VEGF plays an important part in hair follicle cycling and vascular support. However, most therapeutic **strategies focus on stimulating endogenous VEGF rather than applying exogenous VEGF protein. Reviews of androgenetic alopecia treatments emphasize that current FDA-approved options do not include VEGF formulations. Instead, they highlight agents like minoxidil, which indirectly increase VEGF expression, and finasteride, which reduces dihydrotestosterone (DHT), the androgen hormone strongly associated with pattern hair loss. Discussions within the Tressless community reflect this scientific position. Community members frequently discuss how minoxidil, microneedling, and PRP may increase VEGF indirectly. However, there is no widely available or clinically validated topical VEGF product endorsed by regulatory authorities.

User Experiences

The Tressless community discussions show that users often ask whether applying VEGF directly would be more effective than current treatments. Many users reference research showing VEGF upregulation from minoxidil or microneedling and speculate about whether a direct VEGF serum would be superior. However, community responses typically acknowledge that no FDA-approved topical VEGF product exists for hair loss and that most evidence supports indirect stimulation.

Some users who combine microneedling with minoxidil report better results than with minoxidil alone; these are personal accounts, and the 2013 trial behind the idea was a small 12-week pilot. Discussions also note that while PRP is marketed as a growth factor therapy, outcomes vary significantly between clinics.

Importantly, community moderators often caution that experimental peptides or research-grade growth factors sold online lack regulatory oversight and safety data. This mirrors the scientific literature’s emphasis on safety concerns regarding angiogenic factors.

These shared experiences are consistent with published research: VEGF plays a vital biological role, but safe and effective delivery as a direct topical therapy remains unproven.

Final Answer: Is VEGF Available as a Topical Treatment?

Based on current scientific evidence and regulatory approvals, VEGF is not available as an FDA-approved topical treatment for hair loss. In mice, raising VEGF in the skin increases blood vessels around follicles and speeds hair regrowth. In people, minoxidil (approved) and microneedling and platelet-rich plasma (not approved for hair loss) are thought to raise VEGF indirectly, but how much of any benefit comes from VEGF has not been measured.

Published research supports the importance of VEGF in hair biology but does not currently support the direct topical application of VEGF as a safe, effective, and approved therapy for androgenetic alopecia.

References

Dhurat, R., Sukesh, M., Avhad, G., Dandale, A., & Pal, A. (2013). A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: A pilot study. International Journal of Trichology, 5(1), 6–11. https://pubmed.ncbi.nlm.nih.gov/23960389/

Ferrara, N. (2004). Vascular endothelial growth factor: Basic science and clinical progress. Endocrine Reviews, 25(4), 581–611. https://doi.org/10.1210/er.2003-0027

Gentile, P., Garcovich, S., Bielli, A., Scioli, M. G., Orlandi, A., & Cervelli, V. (2015). The effect of platelet-rich plasma in hair regrowth: A randomized placebo-controlled trial. Stem Cells Translational Medicine, 4(11), 1317–1323. https://pubmed.ncbi.nlm.nih.gov/26400925/

Lachgar, S., Charveron, M., Gall, Y., & Bonafe, J. L. (1998). Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. British Journal of Dermatology, 138(3), 407–411. https://pubmed.ncbi.nlm.nih.gov/9580790/

Yano, K., Brown, L. F., & Detmar, M. (2001). Control of hair growth and follicle size by VEGF-mediated angiogenesis. Journal of Clinical Investigation, 107(4), 409–417. https://pubmed.ncbi.nlm.nih.gov/11181640/